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The early apoptotic events induced by environmental pollutants with carcinogenic properties are poorly
understood. Here, we focus on the early cytotoxic effects of benzo[a]pyrene (B[a]P). In F258 rat hepatic
epithelial cells, B[a]P induces intrinsic apoptosis via a mitochondrial dysfunction characterized by the
release of hexokinase II (HKII) from the mitochondria. Cancer cells often have an anomalous cell energy
metabolism; since HKII dysfunction regulates B[a]P-induced apoptosis in F258 cells, but may also alter
cell energy metabolism, HKII release from the mitochondria may represent an important B[a]P-related
carcinogenic issue. Thus in the present study, we aimed at deciphering the mechanisms underlying HKII
dysfunction upon B[a]P exposure.
We show that while glycogen synthase kinase 3 beta (GSK3b) regulated the expression of HKII at the
transcriptional level, glycogen synthase kinase 3 alpha (GSK3a) was involved in B[a]P-induced apoptosis
via a decrease in c-Myc expression. The reduced level of c-Myc caused the relocation of HKII from the
mitochondria to the cytosol, thereby being involved in the formation of reactive oxygen species and
apoptosis.
In conclusion, we show that the couple GSK3a/c-Myc plays a key role in B[a]P-induced early apoptotic
cell signaling via HKII dysfunction.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
Polycyclic aromatic hydrocarbons (PAHs) such as benzo[a]pyr-
ene (B[a]P) are major environmental contaminants, found in ambi-
ent air, cigarette smoke and smoked food. B[a]P exhibits
carcinogenic effects, due to its metabolism by cytochrome P450
into reactive molecules which may form DNA adducts (Zedeck,
1980). Such a genotoxic action along with non-genotoxic effects
of B[a]P may be important for the final outcome: cell survival
and possible mutations, or apoptosis (Huc et al., 2006; Salas and
Burchiel, 1998; Solhaug et al., 2004). Thus, a better characteriza-
tion of the early non-genotoxic events induced by B[a]P may add
important knowledge to the understanding of the mechanisms ofll rights reserved.
/IRSET, Université Rennes 1,
rnard, 35043 Rennes cedex,
794.
fr (D. Lagadic-Gossmann).
l Health, Gydas vei 8, N-0033,
re in Food Toxicology), 180mutagenesis or cytotoxicity. In our previous works, we showed
that following B[a]P treatment, rat epithelial F258 cells underwent
intrinsic apoptosis via a translocation of hexokinase II (HKII) from
mitochondria to cytosol and/or reduction of HKII mRNA levels,
both events being prevented by p53 or Na+/H+ exchanger isoform
1 (NHE1) silencing (Huc et al., 2006, 2007). Since HKII dysfunction
regulates B[a]P-induced apoptosis in F258 cells but may also alter
cell energy metabolism, this event may represent an important
B[a]P-related carcinogenic issue; thus in the present study, we
aimed at deciphering the mechanisms underlying HKII dysfunction
upon B[a]P exposure.
HKII is a glycolytic enzyme that mediates the phosphorylation
of glucose, and couples intra-mitochondrial ATP synthesis to glu-
cose metabolism. HKII favors aerobic glycolysis, cell proliferation
and the maintenance of a low level of reactive oxygen species
(Ahn et al., 2009). HKII has been shown to be over-expressed in
highly malignant tumors (Mathupala et al., 2001; Peng et al.,
2008); and its translocation frommitochondria has been suggested
to play a role in cell death (Pastorino and Hoek, 2003; Plas et al.,
2002). Glycogen synthase kinase 3 (GSK3) has been reported to
be involved in HKII translocation during the mitochondrial
apoptotic pathway (Pastorino et al., 2005).
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activity regulated by many signaling pathways (Ding et al., 2000;
Kim and Kimmel, 2000). The two GSK3 isoforms are not redundant;
indeed, only GSK3b deficiency is lethal in embryogenesis (Hoeflich
et al., 2000). Thus GSK3 isoforms have different functions depend-
ing on cell models and/or the physiological pathway involved
(Beurel and Jope, 2006; Markou et al., 2008). GSK3 is involved in
multiple cellular processes, including metabolism, proliferation,
and cell differentiation (Frame and Cohen, 2001). Recent studies
identify GSK3 as a regulator of the balance between survival and
apoptosis (Hernandez-Davies et al., 2011; Spokoini et al., 2010).
GSK3 can elicit pro-apoptotic effects by regulating anti-apoptotic
transcription factors (b-catenin, HSF-1, Myc) or proteins involved
in mitochondria function (p53, CREB) (Bijur et al., 2000; Ciani
and Salinas, 2005).
The present study aimed at looking for the possible involve-
ment of GSK3 in B[a]P-induced apoptosis. Our data identified
GSK3, and more precisely GSK3a, as a regulator of c-Myc expres-
sion which controls B[a]P-induced mitochondrial dysfunction via
HKII, thus leading to apoptosis.2. Materials and methods
2.1. Chemicals and antibodies
Benzo[a]pyrene (B[a]P), lithium chloride (LiCl), a-naphthoflav-
one (a-NF) and DEVD-AMC (Asp-Glu-Asp-7-amino-4-methyl-
coumarin) were purchased from Sigma Chemicals Co (St Louis,
MO, USA). Peptidic inhibitor of GSK3 (IGSK) was purchased from
Calbiochem (France Biochem, Meudon, France). All these products
were used as a stock solution in dimethyl sulfoxide; final concen-
tration of this vehicle in culture medium was <0.05% (v/v); control
cultures received the same concentration of vehicle as treated cul-
tures. Hoechst 33342 and mouse monoclonal Cytochrome C Oxi-
dase 4 (COX IV) antibody were purchased from Invitrogen
(Invitrogen, France). Rabbit polyclonal anti-c-Myc, goat polyclonal
anti-hexokinase II and mouse monoclonal anti-b-actin were from
Santa Cruz Biotechnology (Tebu-bio SA, Le Perray en Yvelynes,
France). Rabbit polyclonal anti-GSK3a, anti-GSK3a phospho Serine
21, anti-GSK3b, and anti-GSK3b phospho Serine 9 antibodies were
purchased from Cell Signaling (Ozyme, St Quentin-en-Yvelynes,
France). Secondary antibodies conjugated to horseradish peroxi-
dase were from Dako A/S (Glostrup, Denmark).
2.2. Cell culture, apoptosis measurement and Western blotting
immunoassays
The F258 rat liver epithelial cell line was cultured in Williams’E
medium supplemented with 10% fetal calf serum, 2 mM L-gluta-
mine, 5 IU/ml penicillin, and 0.5 mg/ml streptomycin at 37 C un-
der a 5% CO2 atmosphere and treated 24 h following seeding as
previously described (Huc et al., 2004). Microscopical detection
of apoptosis was performed in both floating and adherent cells,
using Hoechst 33342 labeling, as previously described (Huc et al.,
2004). Caspase 3/7 activity assay has been previously described
(Huc et al., 2004). Western blot analysis was performed as previ-
ously described (Huc et al., 2006).
2.3. Transfection of small interfering RNAs (Si RNA)
The following Si RNAs were used: Si RNA oligonucleotides di-
rected against GSK3a (Si Genome SMART pool, NM_080107_00);
GSK3b (Si Genome SMART pool, NM_080108_00); Si RNA negative
control (Si Neg, Si control non-targeting Si RNA#1) (all from Ther-
mo scientific Dharmacon, Colorado); Si RNA against c-Myc (SASIRn01_00089127, SASI Rn01_00089127_AS) (Sigma Aldrich,
France). Transfections of Si RNA were performed in 60-mm dishes
on 90% confluent F258 cells; per dish, Si RNA (100 nM) and 12.5 ll
TransFectin lipid reagent were applied in a final volume of 2 ml
Opti-MEM for 4 h. Transfection rate was evaluated with Si Fluo
and corresponds to 86 ± 5% (n = 4) transfected cells. Transfected
cells were seeded in order to be treated the day after with B[a]P
(5 lM). Previous analysis showed that F258 cells exposure to
B[a]P 5 lM during 36 h, underwent the same apoptotic events as
cells exposed to B[a]P 50 nM, during 72 h (Huc et al., 2004; Tekpli
et al., 2010). Thus, to keep a good rate of protein down-regulation
when transfection with Si RNA was applied, cells were exposed to
B[a]P 5 lM during 36 h.
2.4. Transfection of plasmids
Transfection of vector pExpress-1 with c-Myc gene (Rat MGC
Verified FLcDNA, MRN1768_98079299) (ThermoScientific Open
Biosystems, France) was performed according to manufacturer’s
recommendations. pExpress-1 plasmid control was purchased
from Express Genomics (Express Genomics, Maryland/USA). Trans-
fections of plasmids were performed in 60-mm dishes on 90% con-
fluent F258 cells, in presence of lipofectamine™ 2000 transfection
reagent (Invitrogen, France). Per dish, plasmid (2 lg) and 10 ll of
lipofectamine™ 2000 reagent were applied in a final volume of
2 ml Opti-MEM for 4 h. Transfection rate was evaluated with pEG-
FP-N1 vector (clonetech, USA) and corresponds to 74% transfected
cells. Transfected cells were treated the day after with B[a]P
(5 lM), as for the protocol with Si RNA.
2.5. RNA isolation and analysis
Total RNA extraction and reverse transcription-real time quan-
titative polymerase chain reaction (RT–PCR) were carried as previ-
ously described (Tekpli et al., 2010). The specificity of each gene
amplification was checked at the end of PCR reactions through
the analysis of dissociation curves of the PCR products. The amount
of target cDNA in each sample was established by determining a
fractional PCR threshold cycle number (Ct). The expression levels
of target genes were normalized to the expression of the 18S gene.
The sequences of the primers used for RT–PCR analysis were as fol-
lows: 18S sense: GGAAGCATTTGCCAAGAAT and antisense:
AGTCGGCATCGTTTATGGTC; Hexokinase II sense: CAACATCGT-
CACTGCCATCT and antisense: GGGACCACTTGCTTCCATTA.
2.6. Mitochondrial fractionation
Mitochondrial fractionation was carried as previously described
(Huc et al., 2007).
2.7. Statistical analysis
All data are quoted as mean ± standard error of mean along with
number of observations, n, corresponding to separate cultures. AN-
OVA followed by a Student–Newman-Keuls post-test was used to
compare means. In cases of non-normal distributions, ANOVA fol-
lowed by Dunn post-test was used to compare medians. p < 0.05
was considered statistically significant.
3. Results
3.1. GSK3 is involved in B[a]P-induced apoptosis
Our first set of experiments was carried out to determine a pos-
sible implication of GSK3 in B[a]P-induced apoptosis. F258 cells
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peptidic inhibitor (IGSK) and lithium chloride (LiCl) (Feyt et al.,
2005), and subsequently co-treated 72 h with B[a]P (50 nM). Anal-
ysis of cells with apoptotic morphology (condensed or fragmented
nuclei), and measurement of caspase 3/7 activity demonstrated
that both inhibitors reduced B[a]P-induced apoptosis (Fig. 1A and
B). The two concentrations of LiCl tested gave similar results; fur-
ther experiments were thus carried out with the lowest concentra-
tion. Small interference RNA directed against both GSK3 isoforms
(Si GSK3a/b) efficiently reduced the protein expression of GSK3
isoforms compared to Si negative controls (Si Neg) (Fig. 1C), and
significantly decreased B[a]P-induced apoptosis determined by
fluorescence microscopy and caspase 3/7 activities (Fig. 1D and
E). Note also that, whereas no changes in the phosphorylation state
of Ser 9 in GSK3bwas observed, B[a]P induced a phosphorylation of
GSK3a at Ser 21 (Fig. 1C).Fig. 1. Effects of GSK3 on B[a]P-induced apoptosis. F258 cells were pre-treated 1 h with G
with B[a]P 50 nM, 72 h. F258 cells were transfected with Si Neg or Si GSK3a/b and subseq
analyzed by Hoechst 33342 staining. NP 5 independent experiments. White bars: vehic
spectrofluorimetry, averaged from 5 independent experiments and expressed as Relative
independent experiments. (C) 50 lg of whole cell lysate were separated on 10% SDS–po
anti -GSK3a, -P-GSK3a (Ser 21), -GSK3b, -P-GSK3b (Ser 9), and mouse monoclonal anti-3.2. GSK3a rather than GSK3b is involved in B[a]P-induced apoptosis
Si RNAs targeting either GSK3 isoform were next tested on
B[a]P-induced apoptosis. Even though the Si RNAs directed against
GSK3b (Si GSK3b) were efficient regarding the silencing of this iso-
form (Fig. 2A), they had no effect on B[a]P-induced apoptosis
(Fig. 2B and C). In contrast, regarding the Si RNAs directed against
GSK3a, besides specific reduction of the protein expression
(Fig. 2D), they also significantly reduced the apoptotic effects of
B[a]P (Fig 2E and F).
3.3. GSK3 regulates HKII expression and localization
We next investigated a possible role for GSK3 in B[a]P-induced
down-regulation of HKII mRNA expression (Huc et al., 2007).
Quantitative RT-PCR and SYBR green method showed that GSK3SK3 inhibitors: IGSK (5 lM) or LiCl (10 or 15 mM), and subsequently treated or not
uently treated or not with B[a]P 5 lM during 36 h. (A and D) Apoptotic nuclei were
le; black bars: B[a]P. (B and E) DEVDase (caspases 3/7) activities were measured by
Fluorescence Unit (RFU)/lg proteins normalized by the RFU of control cells. NP 5
lyacrylamide gel electrophoresis. Immunoblots were probed with rabbit polyclonal
b-actin antibodies.
Fig. 2. GSK3 isoforms and B[a]P-induced apoptosis. F258 cells were transfected with Si RNA directed against either the a or the b isoform of GSK3 (Si GSK3a or Si GSK3b) or
with Si RNA control (Si Neg) and subsequently treated with B[a]P 5 lM during 36 h. (A and D) 50 lg of whole cell lysate were separated on 10% SDS–polyacrylamide gel
electrophoresis. Immunoblot were probed with rabbit polyclonal anti- GSK3a, -P-GSK3a (Ser 21), -GSK3b, and P-GSK3b (Ser 9) antibodies or mouse monoclonal anti –b-actin
antibody. Blots are representative of at least 5 independent experiments. (B and E) Apoptotic nuclei were analyzed by Hoechst 33342 staining. NP 5 independent
experiments. White bars: vehicle; black bars: B[a]P. (C and F) DEVDase activities were measured by spectrofluorimetry, averaged from five independent experiments and
expressed as RFU/lg proteins normalized by the RFU of control cells. NP 5 independent experiments.
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B[a]P-induced reduction of HKII mRNA expression (Fig. 3A and
B). In order to gain further insight into the involvement of GSK3
in B[a]P-induced apoptosis, we tested the role of GSK3 in the con-
trol of mitochondrial HKII localization. After a 72 h-treatment with
50 nM B[a]P, HKII was released from mitochondria into cytosol
(Huc et al., 2007), as shown by the decrease in the mitochondrial
expression of HKII (Fig. 3C) or by the loss of co-staining of HKII
with the specific mitochondrial fluoroprobe mitotracker (red)
(Supplementary Fig. 1). GSK3 inhibitors prevented from B[a]P-in-
duced HKII relocation from the mitochondria (Fig. 3C, Supplemen-
tary Fig. 1). GSK3 inhibitors or Si RNA directed against both GSK3
isoforms also prevented from the consequences of the mitochon-
drial dysfunction as estimated by the anion superoxide (O2 )
production (Fig. 3D and Supplementary Fig. 2). Taken together,
these results suggest that B[a]P, through a process involving
GSK3, affects the mRNA expression of HKII and its protein
sub-cellular localization.3.4. GSK3a regulation of c-Myc expression is involved in apoptosis
The proto-oncogene c-Myc has been reported to be involved in
the apoptosis mediated by GSK3 inhibition (Kotliarova et al., 2008),
and also to regulate the expression of HKII (Podar and Anderson,
2010). Thus, as B[a]P might affect c-Myc expression (Fields et al.,
2004; Zhao and Ramos, 1998), we tested the possible involvement
of c-Myc in the B[a]P-induced signaling cascade. We found that
B[a]P markedly reduced the level of c-Myc protein. Such an effect
was prevented by the cytochrome P450-inhibitor: a-naphthoflav-
one (a-NF) (Fig. 4A). Interestingly, both LiCl and IGSK (Fig. 4A) as
well as Si RNA directed against GSK3a (Fig. 4B) abolished the
B[a]P-induced c-Myc down-regulation. Note also that chemical
inhibition of Na+/H+ exchanger isoform 1 (NHE1) and p53 path-
ways also repressed the B[a]P-induced c-Myc down-regulation
(Supplementary Fig. 3).
To counteract the effects of B[a]P on c-Myc expression we trans-
fected the cells with a c-Myc-plasmid construct. Over-expression
Fig. 3. Effects of GSK3 on HKII expression and sub-cellular localization. F258 cells were pre-treated 1 h with GSK3 inhibitors: IGSK (5 lM) or LiCl (10 mM), and subsequently
treated or not with B[a]P 50 nM, 72 h. F258 cells were transfected with Si Neg or Si GSK3a/b, Si GSK3a or Si GSK3b, and subsequently treated or not with B[a]P 5 lM during
36 h. (A and B) Quantitative analysis of HKII mRNA levels in F258 cells. White bars: vehicle; grey bars: B[a]P. NP 5 independent experiments. (C) 15 lg of protein lysate from
mitochondrial fractions were separated on 12% SDS–polyacrylamide gel electrophoresis. Immunoblots were probed with goat polyclonal anti-HKII and mouse monoclonal
anti-COX IV antibodies. COX IV served as a loading control. Data are representative of three independent experiments. (D) Histogram of superoxide anion production obtained
by flow cytometry analysis of cells stained with the superoxide anion sensitive probe DHE. The antioxidant molecule N-acetylcysteine (NAC, 5 mM) prevented the B[a]P-
induced, mitochondria-related reactive oxygen species production. Peaks are representative of 3 independent experiments. White histograms: vehicle; grey histograms:
B[a]P.
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creased B[a]P-induced apoptosis compared to cells transfected
with a control plasmid (Pl Ctr) (Fig. 4C). Furthermore, c-Myc
over-expression inhibited the B[a]P-induced reduction of mito-
chondrial HKII protein level (Fig. 4D). In contrast, silencing of
c-Myc expression using Si RNA directed against c-Myc (Si c-Myc)
significantly enhanced apoptosis (Fig. 4E).
Therefore, in B[a]P-treated cells, the c-Myc decrease controlled by
GSK3a appears to play a significant role in the related apoptosis, and
might constitute the intermediate between GSK3a and HKII, since
c-Myc expression regulated the mitochondrial HKII protein levels.4. Discussion
Our previous works demonstrated the prominent role of trans-
location of HKII from mitochondria to cytosol in B[a]P-induced
apoptosis in F258 cells; p53 and NHE1 activations cross-talked to
deregulate HKII mitochondrial localization as well as its mRNA
expression (Huc et al., 2007). The present study identifies for the
first time the couple GSK3a/c-Myc as a novel target in B[a]P-in-
duced apoptosis (Fig. 5).
Most of the studies regarding the role of GSK3 in apoptosis have
reported that the b isoform is preferentially involved in the apop-
totic cascade, notably by inducing a mitochondrial dysfunction
(Pastorino et al., 2005; Vene et al., 2008). The experiments carried
out with Si RNA targeting either isoform pointed to GSK3a as being
the major isoform involved in our apoptotic model. Most of the
studies linking GSK3 to HKII translocation have shown aninvolvement of the b isoform (Das et al., 2008; Pastorino et al.,
2005). In this context, our study is the first one to clearly evidence
a role for GSK3a in the control of HKII sub-cellular localization. The
apoptotic role of GSK3a has also been reported by others, notably
in cardiac cells (Zhai et al., 2007); thus, a link between GSK3a and
HKII would deserve more focus in the future.
Our previous work demonstrated that B[a]P down-regulates the
mRNA expression of HKII in F258 cells. The present study shed
some light on the underlying intracellular mechanism since GSK3b
seems to be involved in this regulation. But GSK3b appears not to
be involved in B[a]P-induced apoptosis; this might thus indicate
that the decrease in HKII mRNA expression would not be essential
for apoptosis to occur whereas the GSK3a-dependent HKII translo-
cation might be the main key event responsible for the mitochon-
drial dysfunction induced by B[a]P. Nevertheless, it is worth noting
that a recent study in mice showed that in vivo down-regulation of
HKII expression might constitute an efficient therapeutic strategy
towards colon cancer development (Peng et al., 2008). It would
be interesting to test the consequence of HKII mRNA expression
down-regulation on mitochondrial HKII protein level in this latter
model.
The present work further illustrates the differential roles for the
two GSK3 isoforms. Indeed, it has been shown for example that
GSK3a KO mice develop normally whereas targeted deletion of
GSK3b leads to embryonic lethality (Force and Woodgett, 2009);
moreover, whereas Ser 9 phosphorylation of GSK3bmediates path-
ological cardiac hypertrophy, Ser 21 phosphorylation of GSK3a
would play a compensatory role during pressure overload
(Matsuda et al., 2008).
Fig. 4. c-Myc involvement in apoptosis. F258 cells were pre-treated 1 h with either the GSK3 inhibitors, IGSK (5 lM), LiCl (10 mM), or the metabolism inhibitor a-NF (a-
Naphthoflavone, 10 lM), and subsequently treated or not with B[a]P 50 nM, 72 h. F258 cells were transfected with either plasmid allowing over-expression of c-Myc (Pl c-
Myc) or plasmid control (Pl-Ctr), or with Si RNA directed against c-Myc (Si c-Myc), GSK3a (Si GSK3a) or Si Neg, and subsequently treated or not with B[a]P 5 lM during 36 h.
(A, B and D) Cell lysates were separated on 10% SDS–polyacrylamide gel electrophoresis. Immunoblots were probed with rabbit polyclonal anti -HKII, -COX IV, – c-Myc and
mouse monoclonal anti-b-actin antibodies. (C and E) Apoptotic nuclei were analyzed by Hoechst 33342 staining. White bars: vehicle; black bars: B[a]P. N = 3 independent
experiments in all cases.
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Myc expression; this was prevented by inhibition of GSK3. Further-
more, c-Mycwas found to be involved in apoptosis via the control of
HKIImitochondrial localization.Ourdata thereforesuggest a linkbe-
tween GSK3a, c-Myc and HKII. c-Myc is known to be involved in the
regulation of glucose metabolism (Dang et al., 2009; Valera et al.,
1995); one might then suppose that the decrease in c-Myc expres-
sionmay lead to a decrease in intracellular glucose, thereby favoring
the disruption of HKII frommitochondria.
It remains to be determined if the decrease of c-Myc expression
is involved in the regulation of HKII mRNA expression by GSK3b. In
support to this hypothesis, it has been shown that c-Myc can trans-
activate the HKII gene (Kim et al., 2007). When considering the reg-
ulation of c-Myc expression by GSK3, it is worth noting that it has
been shown that GSK3 is capable of binding c-Myc in nucleus,
which would allow the Thr-58 phosphorylation of c-Myc and
hence regulation of its stability (Gregory et al., 2003). Finally, a
very recent study has evidenced, by using statins, that the enzyme
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA
reductase) might be a critical regulator of c-Myc phosphorylation,activation, and tumorigenic properties, since an inhibition of
HMG-CoA reductase blocked the phosphorylation and activation
of c-Myc (Cao et al., 2011). As B[a]P has been previously shown
to inhibit this enzyme in our apoptosis model (Tekpli et al.,
2010), such a link between HMG-CoA reductase and c-Myc expres-
sion would deserve further investigation.
In conclusion, the present study evidences a new role for GSK3a
in B[a]P-induced cell death via changes in c-Myc level and HKII
sub-cellular localization. As HKII is over-expressed in various types
of cancer cells (Mathupala et al., 2001; Peng et al., 2008), our study
might help identifying new anticancer therapeutic targets to mod-
ulate HKII tumor effects. Finally, our data provide new information
regarding the signaling pathways induced by B[a]P which regulate
the delicate balance between proliferation, cell cycle arrest, cell
survival and apoptosis.5. Conflict of interest
None declared.
Fig. 5. Schematic summary of the role of GSK3 in the B[a]P-induced effects on HKII
in F258 cells.
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